Covered recipient · General Payments record
PAUL M SCHWARTZ
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$542.64
- Reported across 28 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $194.30 | 9 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $76.96 | 3 |
| Bayer HealthCare Pharmaceuticals Inc. | $27.88 | 1 |
| Astellas Pharma US Inc | $22.18 | 1 |
| Acerta Pharma LLC | $20.63 | 1 |
| GlaxoSmithKline, LLC. | $18.80 | 1 |
| Abbott Laboratories | $13.96 | 1 |
| Amgen Inc. | $13.89 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (9)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $13.96 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124809039 | CMS |
| ABBVIE INC. | $33.17 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106045334 | CMS |
| ABBVIE INC. | $26.45 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106045336 | CMS |
| ABBVIE INC. | $17.34 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106045338 | CMS |
| Amgen Inc. | $13.89 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117678473 | CMS |
| Astellas Pharma US Inc | $22.18 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139361569 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.63 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104731673 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $27.88 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086112794 | CMS |
| GlaxoSmithKline, LLC. | $18.80 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116551853 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.